$0.17 EPS Expected for AngioDynamics, Inc. (ANGO)

September 16, 2018 - By Mark Babin

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.5 in Q2 2018. Its up 0.04, from 1.46 in 2018Q1. It improved, as 10 investors sold AngioDynamics, Inc. shares while 44 reduced holdings. 29 funds opened positions while 52 raised stakes. 35.30 million shares or 1.16% more from 34.89 million shares in 2018Q1 were reported.
Rothschild Asset Management owns 0.02% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 97,729 shares. Tower Research Capital Lc (Trc) holds 0% or 1,027 shares in its portfolio. Envestnet Asset Management accumulated 5,358 shares. Jacobs Levy Equity Mngmt invested in 215,078 shares or 0.08% of the stock. Macquarie Grp Limited holds 0% or 15,500 shares. Texas Permanent School Fund owns 23,755 shares. Ameriprise Financial Inc holds 0.01% or 806,922 shares. State Of Tennessee Treasury Department has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Voya Inv Management Llc has 55,985 shares. 30,000 are owned by Texas Yale. Ameritas Inv Ptnrs invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Citadel Advisors Llc reported 167,284 shares. Bluemountain Capital Mngmt Lc holds 31,654 shares or 0.01% of its portfolio. Connor Clark & Lunn Investment Mngmt Ltd accumulated 164,089 shares. Swiss National Bank & Trust reported 66,300 shares stake.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.17 EPS on September, 27.They anticipate $0.05 EPS change or 41.67 % from last quarter’s $0.12 EPS. ANGO’s profit would be $6.30 million giving it 34.97 P/E if the $0.17 EPS is correct. After having $0.20 EPS previously, AngioDynamics, Inc.’s analysts see -15.00 % EPS growth. The stock decreased 0.88% or $0.21 during the last trading session, reaching $23.78. About 212,645 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.51% since September 16, 2017 and is uptrending. It has outperformed by 14.89% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 2 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Angiodynamics had 3 analyst reports since March 29, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, April 3 by Raymond James. Canaccord Genuity maintained it with “Hold” rating and $1700 target in Thursday, March 29 report. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) rating on Monday, April 2. Canaccord Genuity has “Hold” rating and $17 target.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $881.65 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 54.05 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Another recent and important AngioDynamics, Inc. (NASDAQ:ANGO) news was published by Seekingalpha.com which published an article titled: “AngioDynamics to acquire RadiaDyne” on September 13, 2018.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.